Novavax Shorts on Edge as Russia Plague Fears Spread

Impact · against what's priced in

The rally in Novavax, Moderna, and Emergent BioSolutions is driven by sentiment and short-covering rather than fundamental catalysts, as the suspected outbreak is not yet confirmed and Novavax's technology is not suited for bacterial infections. Vistra's federal loan supports its existing narrative of expanding nuclear capacity for AI data centers, which the market already acknowledges.

VST+0.10

Already priced in

The price assumes

the general market narrative that AI and data centers will increase future power demand in ERCOT and PJM